Combination therapy for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new combination of a migraine drug (rimegepant) with standard chemotherapy (AG) as a first treatment for advanced pancreatic cancer. It aims to see if this combo can help shrink tumors or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with pancreatic cancer that has spread to other parts of the body.
- You have not had any prior chemotherapy, radiation, or experimental treatment for this cancer.
- You are generally able to take care of yourself (ECOG 0-1).
- Your organs are working well enough, as confirmed by blood tests.
- You do not have certain serious conditions like heart disease, uncontrolled diabetes, or severe diarrhea.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
This trial tests a new drug called ONT01 combined with two standard chemo drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread and is no longer responding to first treatment. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of two chemotherapy drugs, nab-paclitaxel and gemcitabine, as the first treatment for pancreatic cancer that has spread. The goal is to shrink tumors and improve survival.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial tests a combination of chemotherapy with two newer drugs (SHR-1701 and apatinib) as the first treatment for advanced pancreatic cancer. The goal is to see if this combination is safe and effective in slowing cancer growth.
Hear when a new Metastatic Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.